EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Articles

Exploring the science, practice, and people shaping the future of early developmental evaluation.

From Fixing to Flourishing: A Brief History of Autism in America & Beyond

If you’ve spent time around someone on the autism spectrum, you’ve probably learned the basics: use people-first language, be empathetic, hold space. […]

…

CARS-2 vs. ADOS-2: Choosing the Right Autism Assessment Tool for Your Practice

Choosing the right autism assessment tool has direct consequences for your practice’s diagnostic accuracy, patient throughput, staffing requirements, and operational capacity. For […]

…

ADI-R for Autism Diagnosis: What Clinicians Should Know

The Autism Diagnostic Interview-Revised (ADI-R) is one of the most widely used and thoroughly researched caregiver interview tools in autism diagnosis. Alongside […]

…

Why Early Autism Diagnosis Is a Growth Strategy, Not Just a Clinical One

Most ABA practice owners I talk to already believe in early diagnosis. They know the clinical case. They’ve seen what happens when […]

…

EarliPoint Receives FDA Clearance to Expand Autism Diagnosis and Assessment Up to Age 8

Expanded indication enables broader access to objective, biomarker-based autism assessment and measurement of outcomes over time Plymouth, MN, March 12, 2026 — […]

…

Local SEO for ABA Therapy Providers: A Step-by-Step Guide

Most ABA practices have a website. Most have a Google Business Profile. And most are invisible to the families who need them. […]

…
Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder